A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.

This is a Phase I safety study testing a new inhaled drug called HRS-9821 in healthy adults and in people with chronic obstructive pulmonary disease (COPD). It evaluates how safe the drug is, how it is absorbed by the body, and what effects it has. **You may be eligible if...** - You are a healthy non-smoker aged 18–50 (for the healthy volunteer portion), OR - You are a man or woman aged 40–75 with a confirmed COPD diagnosis, and have smoked for at least 10 pack-years - You have a BMI of 18–33 kg/m² - Your ECG (heart tracing) is normal or not clinically significant **You may NOT be eligible if...** - You have a prolonged QTcF interval on ECG (≥450 ms) - You recently donated blood or had significant blood loss (within 4 weeks) - You are a healthy volunteer who currently smokes or quit smoking less than 12 months ago - You are unable to use the inhalation device correctly Talk to your doctor to see if this trial is right for you.